Winch Advisory Services LLC Acquires 82 Shares of Johnson & Johnson (NYSE:JNJ)

Winch Advisory Services LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJFree Report) by 3.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,207 shares of the company’s stock after purchasing an additional 82 shares during the quarter. Winch Advisory Services LLC’s holdings in Johnson & Johnson were worth $344,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in the business. Independent Advisor Alliance increased its holdings in Johnson & Johnson by 0.9% in the 2nd quarter. Independent Advisor Alliance now owns 153,337 shares of the company’s stock worth $25,380,000 after acquiring an additional 1,327 shares during the last quarter. Cypress Wealth Services LLC boosted its stake in Johnson & Johnson by 5.4% in the 2nd quarter. Cypress Wealth Services LLC now owns 9,725 shares of the company’s stock worth $1,547,000 after purchasing an additional 497 shares during the period. King Luther Capital Management Corp boosted its stake in Johnson & Johnson by 0.3% in the 2nd quarter. King Luther Capital Management Corp now owns 643,435 shares of the company’s stock worth $106,501,000 after purchasing an additional 2,027 shares during the period. DORCHESTER WEALTH MANAGEMENT Co boosted its stake in Johnson & Johnson by 0.6% in the 3rd quarter. DORCHESTER WEALTH MANAGEMENT Co now owns 75,495 shares of the company’s stock worth $11,758,000 after purchasing an additional 414 shares during the period. Finally, Dimensional Fund Advisors LP boosted its position in shares of Johnson & Johnson by 5.1% during the 2nd quarter. Dimensional Fund Advisors LP now owns 8,843,038 shares of the company’s stock valued at $1,463,594,000 after acquiring an additional 430,445 shares during the last quarter. 68.40% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages recently weighed in on JNJ. Morgan Stanley decreased their price objective on Johnson & Johnson from $170.00 to $169.00 and set an “equal weight” rating on the stock in a report on Wednesday, January 24th. StockNews.com raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Tuesday. Barclays boosted their target price on Johnson & Johnson from $158.00 to $162.00 and gave the company an “equal weight” rating in a research note on Thursday, October 12th. UBS Group raised Johnson & Johnson from a “neutral” rating to a “buy” rating and boosted their target price for the company from $167.00 to $180.00 in a research note on Friday, December 1st. Finally, Royal Bank of Canada restated an “outperform” rating and set a $181.00 price target on shares of Johnson & Johnson in a research report on Wednesday, January 24th. Eight analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, Johnson & Johnson currently has an average rating of “Moderate Buy” and an average target price of $176.14.

View Our Latest Stock Analysis on Johnson & Johnson

Johnson & Johnson Trading Up 1.5 %

Johnson & Johnson stock opened at $158.07 on Wednesday. The company has a market capitalization of $380.52 billion, a price-to-earnings ratio of 11.45, a price-to-earnings-growth ratio of 2.63 and a beta of 0.53. The company has a current ratio of 1.21, a quick ratio of 0.96 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 12 month low of $144.95 and a 12 month high of $175.97. The business’s fifty day simple moving average is $158.08 and its two-hundred day simple moving average is $159.05.

Johnson & Johnson (NYSE:JNJGet Free Report) last announced its quarterly earnings results on Tuesday, January 23rd. The company reported $2.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.28 by $0.01. The firm had revenue of $21.40 billion for the quarter, compared to the consensus estimate of $21.02 billion. Johnson & Johnson had a return on equity of 36.75% and a net margin of 37.79%. The company’s quarterly revenue was down 9.7% on a year-over-year basis. During the same period in the prior year, the company posted $2.35 earnings per share. As a group, equities analysts predict that Johnson & Johnson will post 10.66 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 5th. Investors of record on Tuesday, February 20th will be given a dividend of $1.19 per share. This represents a $4.76 dividend on an annualized basis and a yield of 3.01%. The ex-dividend date is Friday, February 16th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 34.47%.

About Johnson & Johnson

(Free Report)

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment provides skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR. CI:LABO, NEUTROGENA, and OGX brands; baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; TYLENOL acetaminophen products; SUDAFED cold, flu, and allergy products; BENADRYL and ZYRTEC allergy products; MOTRIN IB ibuprofen products; NICORETTE smoking cessation products; and PEPCID acid reflux products.

Further Reading

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJFree Report).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.